ARTÍCULO

Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.

Autores: García Velloso, María José; Bastarrika Alemáñ, Gorka; De Torres Tajes, Juan Pablo; Lozano Escario, María Dolores; Sánchez Salcedo, Pablo Antonio; Sancho Rodriguez, Lidia; Núñez Córdoba, Jorge María; Campo Ezquibela, Aránzazu; Alcaide Ocaña, Ana Belén; Torre Buxalleu, Wenceslao; Richter Echevarría, José Ángel; Zulueta Francés, Javier Joseph
Título de la revista: LUNG CANCER
ISSN: 0169-5002
Volumen: 97
Páginas: 81-86
Fecha de publicación: 2016
Resumen:
A major drawback of lung cancer screening programs is the high frequency of false-positive findings on computed tomography (CT). We investigated the accuracy of selective 2-[fluorine-18]-fluoro-2-deoxy-d-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan in assessing radiologically indeterminate lung nodules detected in lung cancer screening. Methods: FDG PET/CT was performed to characterize 64 baseline lung nodules >10 mm and 36 incidence nodules detected on low-dose CT screening in asymptomatic current or former smokers (83 men, age range 40¿83 years) at high risk for lung cancer. CT images were acquired without intravenous contrast. Nodules were analyzed by size, density, and metabolic activity and visual scored on a 5-point scale for FDG uptake. Nodules were classified as negative for malignancy when no FDG uptake was observed, or positive when focal uptake was observed in the visual analysis, and the maximum standardized uptake value (SUVmax) was measured. Final diagnosis was based on histopathological evaluation or at least 24 months of follow-up. Results: A total of 100 nodules were included. The prevalence of lung cancer was 1%. The sensitivity, specificity, NPV and PPV of visual analysis to detect malignancy were 84%, 95%, 91%, and 91%, respectively, with an accuracy of 91% (AUC 0.893). FDG PET/CT accurately detected 31 malignant tumors (diameters 9¿42 mm, SUVmax range 0.6¿14.2) and was falsely negative in 6 patients. With SUVmax threshold